Literature DB >> 34288249

Letter to the Editor regarding article "J point elevation in high precordial leads associated with risk of ventricular fibrillation".

Alper Karakuş1, Kadir Uğur Mert2, Bülent Görenek2.   

Abstract

Entities:  

Year:  2021        PMID: 34288249      PMCID: PMC8293605          DOI: 10.1111/anec.12867

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


× No keyword cloud information.
Dear Editor, We have read with great interest the recent article entitled “J point elevation in high precordial leads associated with risk of ventricular fibrillation” by Yuki Hasegawa et al., (2020). In their case–control study, the authors compared the electrocardiogram (ECG) of 35 patients with idiopathic ventricular fibrillation (IVF) versus those of 105 age‐ and gender‐matched control subjects and with those of 15 patients with Brugada syndrome (BrS). They evaluated the frequency of J point elevation ≥0.1 mV in the 3rd and 4th intercostal spaces. The authors concluded that the prevalence of J point elevation in the 3rd intercostal spaces was high in patients with IVF. We appreciate the authors on this successful study and would like to address some points to merit more attention. There are conflicting results of population‐based studies of J point elevation seen on surface ECG. The location of the J wave also varied in the different patient groups (Rosso et al., 2008). Importantly, this pattern can be seen in the setting of younger age, lower heart rate, electrolyte imbalance, hyperthermia (fever), and usage of pharmacological agents (antiarrhythmics, antianginals, psychotropics, or anesthetics/analgesics drugs) (Antzelevitch et al., 2017; Nam, 2012). Furthermore, the presence of the abovementioned factors in J‐wave syndrome during the peri‐event period can trigger the malignant arrhythmia and influence the association with sudden cardiac arrest (Priori et al., 2015). Therefore, it is necessary to include clinical data of modular factors on analysis for making clear the relationship between J point elevation in high precordial leads and ventricular fibrillation episodes. Additionally, the statistical measurement used in the study seems limited in its ability to assess relative risk. In addition, there are some methodological issues and scant data regarding skewness in the article. Especially, small sample sized make us think can be a violation of normality and so the Mann‐Whitney U test could have been appropriate. Also, comparisons between IVF patients with and without J point and BrS should have been used one‐way ANOVA or Kruskal‐Wallis test because there are three groups (Armitage, 2008). Conclusively, It can be argued that J point elevation in the 3rd intercostal spaces may be a marker for “increased risk” in idiopathic ventricular fibrillation. The results could only reflect the ECG correlates of IVF but not its prognostic power for ventricular fibrillation episodes. It would be safe to say the link between J point elevation in high precordial leads and malignant arrhythmias after evaluation of the relation between the abovementioned clinical variables and ECG which was assessed by using Cox proportional hazards regression analysis in this study.

CONFLICT OF INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

AUTHOR CONTRIBUTIONS

A.K., K.U.M., and B.G. involved in concept, design, supervision, analysis and interpretation, literature search, writing, and critical review.

ETHICAL APPROVAL

The protocol was approved by the Institutional Ethics Committee, Eskisehir Osmangazi University, Turkey.

DATA AVAILABILITY STATEMENT

Data openly available in a public repository that issues datasets with DOIs.
  5 in total

Review 1.  2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).

Authors:  Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen
Journal:  Europace       Date:  2015-08-29       Impact factor: 5.214

Review 2.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Europace       Date:  2017-04-01       Impact factor: 5.214

3.  J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance.

Authors:  Raphael Rosso; Evgeni Kogan; Bernard Belhassen; Uri Rozovski; Melvin M Scheinman; David Zeltser; Amir Halkin; Arie Steinvil; Karin Heller; Michael Glikson; Amos Katz; Sami Viskin
Journal:  J Am Coll Cardiol       Date:  2008-10-07       Impact factor: 24.094

Review 4.  Idiopathic ventricular fibrillation, early repolarization and other J wave-related ventricular fibrillation syndromes: from an electrocardiographic enigma to an electrophysiologic dogma.

Authors:  Gi-Byoung Nam
Journal:  Circ J       Date:  2012-11-07       Impact factor: 2.993

5.  J point elevation in high precordial leads associated with risk of ventricular fibrillation.

Authors:  Yuki Hasegawa; Hiroshi Watanabe; Yasuhiro Ikami; Sou Otsuki; Kenichi Iijima; Nobue Yagihara; Daisuke Izumi; Tohru Minamino
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-12-27       Impact factor: 1.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.